Simultaneous in situ genotyping and phenotyping of human papillomavirus cervical lesions: Comparative sensitivity and specificity

A K Graham, C S Herrington, J O’D McGee

Abstract

The sensitivity and specificity of immunocytochemistry were compared with those of non-isotopic in situ hybridisation (NISH) for the direct detection of human papillomaviruses in biopsy specimens. Four monoclonal antibodies raised to the capsid protein of HPV16 were less specific than NISH: all four reacted with lesions containing HPV33, and HPV18. Absolute discrimination of HPV types, therefore, was not possible with the monoclonal antibodies used in this study. The relative sensitivities of these antibodies were also lower than NISH. Sequential immunocytochemistry and NISH on the same section showed that 2.9–13.0 times as many cells were positive by NISH than by immunocytochemistry using the most sensitive monoclonal antibody.

These data indicate that NISH has higher diagnostic specificity and sensitivity than immunocytochemistry using monoclonal antibodies to the HPV16 capsid protein.

Human papillomaviruses (HPV) are associated with lesions of squamous epithelia.1 The isolation and characterisation of HPV DNA has allowed them to be classified into over 50 subtypes based on nucleic acid sequence.2 Pathological lesions from different anatomical sites and of different histological patterns are associated with different viral subtypes.3 In particular, anogenital lesions are associated with types 6, 11, 16, 18, 31, 33, 35 and others.4 Within this group HPV types segregate according to the histopathological features, with benign and mildly dysplastic lesions associated with HPV6 and 11, and severe dysplasia and invasive carcinoma associated with 16, 18, 31, 33, and 35.4 The detection and precise typing of HPV types is therefore important in the study of the natural history, epidemiology, and possible oncogenic potential of HPV infection.

Papillomaviruses can be detected in clinical samples in a variety of ways. These depend on being able to show the components of the virus within cells and tissues and therefore entail the detection of either protein or nucleic acid. Viral proteins can be visualised by immunocytochemical techniques and these have been performed with both polyclonal5–7 and monoclonal antibodies.8 Many viral proteins to which antibodies are directed, however, are expressed in a cycle dependent manner and their demonstration depends on synthesis directed by the virus. This requires that the appropriate part of the viral genome is retained within the nucleus and that it is being transcribed/translated. Polyclonal antibodies raised to the bovine papillomavirus (BPV) capsid protein have been used to detect HPV types in human biopsy specimens, because they cross react with several human viral subtypes.5–7 Using molecular techniques, bacterial fusion proteins can be synthesised and used as immunogens in mice. Monoclonal antibodies to specific viral proteins have therefore been generated with a view to achieving viral specificity.8 The use of the HPV16 L1 (or capsid) protein has led to the production of several antibodies of varying specificity. To date, studies of these antibodies by both Western blotting and immunocytochemistry have been confined to lesions infected with HPV2/6/11/16 and 18.8 Several of these antibodies seem to be specific for HPV16 in tissue sections, although one (designated 1C6) recognises the HPV18 L1 protein on Western blots.7 The latter antibody, however, was not tested on a tissue section infected with HPV18.8 The description of further HPV subtypes associated with premalignant and malignant disease of the cervix, particularly HPV31, 33, and 35, warrants further investigation of these antibodies.

Immunocytochemistry and non-isotopic in situ hybridisation (NISH) have been combined in the analysis of phenotypic and genotypic characteristics of individual lesions infected with Epstein-Barr virus (EBV),9 cytomegalovirus (CMV),10–13 and HPV.8,16–18 Initially, parallel sections were investigated using both isotopic10–11 and non-isotopic in situ hybridisation,19 but more recently NISH and immunocytochemistry have been combined on the same tissue section.16–19 Polyclonal antibodies to BPV are widely used for the detection of HPV in clinical material8–7 and have been combined with in situ hybridisation using genomic15–17 and oligonucleotide probes to HPV types.17 The latter approach, however, is of limited comparative and diagnostic use as only part of the viral genome is detectable with limited sensitivity. Polyclonal antibodies to HPV16 have also been isolated but show considerable cross reactivity with other HPV types, including HPV1, 2, 6, and 11.8

In this study we analysed the immuno-
cytochemical characteristics of four monoclonal antibodies raised to the HPV16 L1 protein in lesions infected with a variety of HPV subtypes, including HPV31 and 33, to determine their HPV specificity. An additional aim was to compare the sensitivity of immunocytochemistry with that of NISH.

To date, monoclonal antibodies to HPV capsid proteins have only been combined on parallel sections with isotopic in situ hybridisation or non-isotopic in situ hybridisation. We have developed a technique which combines NISH and immunocytochemistry to produce substrate products in contrasting colours within the same tissue section. This has shown that cells containing HPV genome are more frequently detected than cells producing HPV capsid protein.

**Methods**

**SLIDE PREPARATION**

All biopsy specimens (from 1972–86) were fixed in formalin and embedded in paraffin wax. Sections (5 μm) were cut and mounted on to four-well multispot slides (Hendley, Essex) coated with aminopropyltriethoxysilane as previously described. After overnight incubation at 60°C sections were dewaxed following incubation at 75°C for 15 minutes by serial immersion in xylene twice (10 minutes each wash), 99% ethanol twice (10 minutes each wash), tap and then distilled water.

**IMMUNOCYTOCHEMISTRY**

Four monoclonal antibodies raised against the L1 protein were obtained. These have been designated 5A4, 1C6, 3D1 and 8C4. Dewaxed sections were incubated with the appropriate antibody diluted 1:50 in 50 mM TRIS HCl, 100 mM NaCl (pH 7-2) (TBS) for 30–60 minutes at 22°C. Dilutions lower than 1:50 gave unacceptable background. Subsequent detection followed one of two procedures:

1. After washing for five minutes in TBS sections were sequentially incubated in rabbit anti-mouse (Dako, UK) diluted 1:50 inTBS, then alkaline phosphatase anti-alkaline phosphatase complex (APAAP) diluted 1:50 in TBS. Signal was detected using nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indoly phosphate (BCIP).

2. After washing in TBS sections were sequentially incubated in biotinylated rabbit anti-mouse [F(ab′)2 fragment] (Dako, UK) diluted 1:200 in TBS, then streptavidin peroxidase (Dako, UK) diluted 1:100 in TBS containing 5% non-fat milk. Signal was detected using aminoethylcarbazole (AEC). This was prepared by dissolving 2 mg AEC in 1:2 ml dimethylsulphoxide followed by addition to 10 ml sodium acetate buffer (pH 5.0). 

**UNMASKING OF NUCLEIC ACIDS**

Before in situ hybridisation sections were incubated in proteinase K at a concentration of 500 μg/ml (about 20 units/mg protein) in phosphate buffered saline (PBS) for 15 minutes at 37°C. Slides were washed thoroughly in distilled water followed by PBS and dried at 75°C.

**NON-ISOTOPIC IN SITU HYBRIDISATION**

Probes for HPV types 6, 11, 16, 18, 31, and 33 were labelled with biotin by nick translation, as described previously. Aliquots of hybridisation mix (9 μl) containing 10–20 ng of the appropriate biotinylated probe were added to each well on multispot slides, covered with a glass coverslip (Chance, UK), and the slides placed in a moist Terasaki plate. Hybridisation mix consisted of 50% formamide, 5% dextran sulphate (BDH, UK), 2 × SSC, and 0-05 mol/l TRIS-HCl (pH 7-3); 1 × SSC = 0-15 mol/l sodium chloride, 0-015 mol/l sodium citrate. Sections and probes were simultaneously denatured at 95°C for 15 minutes on a solid stainless steel plate in a hot air oven and then hybridised at 42°C for two hours.

**DETECTION OF HYBRIDISATION SIGNAL**

Preliminary experiments were carried out under high stringency conditions to ensure that the biopsy specimens contained only one HPV type.

Slides were washed in three changes of 4 × SSC at 22°C (five minutes each change). They were then soaked in blocking agent TBT (0-05 mol/l TRIS-HCl, 0-10 mol/l NaCl (pH 7.2) containing 3% bovine serum albumin and 0-05% Triton 100 (v/v)) at 22°C for 10 minutes. Probe hybridisation was detected using either streptavidin peroxidase or APAAP, as described for immunocytochemistry, with monoclonal anti-biotin, diluted 1:50 in TBT as the primary antibody.

**COMBINED NISH AND IMMUNOCYTOCHEMISTRY**

Immunocytochemistry and NISH were performed sequentially according to the above methods. Development of antibody staining using the APAAP method was followed by NISH using the peroxidase-AEC procedure and vice versa. Unmasking was performed before NISH, irrespective of the order in which immunocytochemistry and NISH were carried out.

**QUANTITATION OF STAINING**

After combined NISH and immunocytochemistry the total number of positive cells (red or blue) and those positive by immunocytochemistry (blue) were counted by three independent observers. The positivity was expressed as the ratio of immunocytochemistry and NISH positive cells to immunocytochemistry positive cells and represents the ratio of cells containing viral genome to those containing capsid protein.

**Results**

**COMBINED IMMUNOCYTOCHEMISTRY AND NISH**

Using 5A4 and the APAAP detection system
with NBT/BCIP as substrate on a biopsy specimen infected with HPV16, nuclei containing the viral capsid protein can be clearly seen in the superficial layers of the epithelium (fig 1A). To compare the sensitivity of immunocytochemistry and NISH, procedures were performed sequentially on a consecutive section to that shown in fig 1A. This showed that NISH detects many more HPV16 positive cells than 5A4 (fig 1B). In the course of working out this sequential protocol, it was found that if in situ hybridisation were performed first, followed by immunocytochemistry, no viral antigen was demonstrable. This is likely to be due to the destruction of the viral antigen by either the temperature required for in situ hybridisation or proteinase K digestion (table 1). Alternatively, the NISH reaction product may occlude access of antibody to HPV16 capsid epitopes.

If the colour development scheme is reversed, such that antigen is stained red with peroxidase substrate (AEC) and nucleic acid blue with alkaline phosphatase substrate (NBT/BCIP), all antigen positive cells also contain viral nucleic acid (figs 2A and B). Thus the sum of blue and red stained cells shown in fig 3 represents those epithelial cells containing viral genome.

**Table 1** Alternating sequence of immunocytochemistry and NISH affects immunocytochemistry result

<table>
<thead>
<tr>
<th>Combined immuno-</th>
<th>Immunocytochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>cytochemistry and NISH*</td>
<td>reaction</td>
</tr>
<tr>
<td>(a) Immunocytochemistry = blue</td>
<td>Positive (fig 1)</td>
</tr>
<tr>
<td>(b) NISH = red</td>
<td>Positive (fig 2)</td>
</tr>
<tr>
<td>(a) Immunocytochemistry = red</td>
<td>Negative</td>
</tr>
<tr>
<td>(b) NISH = blue</td>
<td>Negative</td>
</tr>
<tr>
<td>(a) NISH = blue</td>
<td>Negative</td>
</tr>
<tr>
<td>(b) Immunocytochemistry = blue</td>
<td>Negative</td>
</tr>
</tbody>
</table>

*Procedure (a) was followed by (b).

**Relative Sensitivity of Immunocytochemistry and NISH**

The absolute number of immunocytochemical and NISH positive cells and the NISH:immunocytochemical ratio in four patients are shown in table 2. The lowest ratio was 2·4 and the highest 32·7. Overall, however, the most sensitive antibody (5A4) gave an NISH:immunocytochemical ratio of 2·9−13·0. There was also a considerable difference in relative sensitivity—that is, NISH/immunocytochemical ratio—in two blocks taken from the same (dysplastic) lesion (table 2, case 1). The total number of antibody and NISH positive cells, together with the NISH:immunocytochemical ratio for three of the patients shown in table 2 are shown in table 3.

In a larger series of 18 cases there were no antibody positive cells in some patients despite the presence of the viral genome, as shown by NISH (table 4). In this series it was also shown that biopsy specimens positive for HPV18 and HPV33 (cases 17 and 18) by NISH also stained with one or more antibodies.

Figure 1 Cervical lesion infected with HPV18, histologically CIN1 with wart virus infection. Combined immunocytochemistry using antibody 1C6, developed as blue/black using NBT/BCIP and NISH, developed as red using AEC. Some nuclei containing both immunocytochemical and NISH signals (large arrow) and a binucleate cell in which one nucleus contains antigen (and nucleic acid), and the other only nucleic acid can be seen (small arrow).

Figure 2 (A) Detection of capsid protein using avidin peroxidase-AEC. Protein containing cells are red-brown. (B) Combination of immunocytochemistry, developed as red, and NISH, developed as blue, showing that all nuclei containing capsid protein also contain viral nucleic acid.
**HPV detection by monoclonal antibodies and NISH**

Figure 3 (A) Capsid protein detection in a condyloma acuminatum. Nuclei positive with antibody 5A4 can be seen as blue, detected using the APAAP-NBT/BCIP method. (B) Combination of immunocytochemistry and NISH. Many more nuclei contain viral nucleic acid (red) than capsid protein (blue). Note that both signals are present in some nuclei (arrows).

<table>
<thead>
<tr>
<th>Case No</th>
<th>HPV</th>
<th>Antibody</th>
<th>Immunocytochemistry positive</th>
<th>NISH positive</th>
<th>Ratio</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>16</td>
<td>5A4</td>
<td>31</td>
<td>402</td>
<td>13-0</td>
<td>CIN3 + koilocytes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1C6</td>
<td>24</td>
<td>457</td>
<td>19-0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3D1</td>
<td>14</td>
<td>422</td>
<td>30-1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8C4</td>
<td>12</td>
<td>392</td>
<td>32-7</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>5A4</td>
<td>23</td>
<td>258</td>
<td>11-2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1C6</td>
<td>28</td>
<td>158</td>
<td>5-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D1</td>
<td>15</td>
<td>146</td>
<td>9-7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8C4</td>
<td>18</td>
<td>194</td>
<td>10-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>5A4</td>
<td>100</td>
<td>536</td>
<td>5-4</td>
<td>Condyloma</td>
</tr>
<tr>
<td></td>
<td>1C6</td>
<td>47</td>
<td>493</td>
<td>10-5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D1</td>
<td>66</td>
<td>583</td>
<td>8-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8C4</td>
<td>61</td>
<td>512</td>
<td>8-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>18</td>
<td>5A4</td>
<td>129</td>
<td>304</td>
<td>2-4</td>
<td>CIN1 + koilocytes</td>
</tr>
<tr>
<td></td>
<td>1C6</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D1</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8C4</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>33</td>
<td>5A4</td>
<td>284</td>
<td>825</td>
<td>2-9</td>
<td>Condyloma</td>
</tr>
<tr>
<td></td>
<td>1C6</td>
<td>115</td>
<td>754</td>
<td>6-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D1</td>
<td>133</td>
<td>724</td>
<td>5-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9C4</td>
<td>190</td>
<td>859</td>
<td>4-5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2 Relative sensitivity of immunocytochemistry and NISH**

Table 3 Absolute and relative sensitivity of immunocytochemistry and NISH

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Immunocytochemistry</th>
<th>NISH</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>5A4</td>
<td>438</td>
<td>2021</td>
<td>4-6</td>
</tr>
<tr>
<td>1C6</td>
<td>214</td>
<td>1862</td>
<td>8-7</td>
</tr>
<tr>
<td>3D1</td>
<td>228</td>
<td>1875</td>
<td>8-2</td>
</tr>
<tr>
<td>8C4</td>
<td>281</td>
<td>1957</td>
<td>7-6</td>
</tr>
</tbody>
</table>

*These data represent the overall immunocytochemistry and NISH positive cells, together with the resultant NISH:immunocytochemistry ratio from cases 1, 11, and 18 shown in table 2.

**Discussion**

The production of monoclonal antibodies to viral proteins is prompted by two main considerations: the investigation of viral protein expression and the detection of viral infection in clinical samples. For the latter aim to be achieved, the viral protein to which the antibody is directed must be synthesised. Thus only cells in which the viral capsid protein is present will produce a positive signal with the antibodies used in this study. The fact that positivity with these antibodies is confined to the superficial layers of the epithelium supports the hypothesis that capsid protein synthesis is a late event in viral replication and occurs immediately before virus shedding. The demonstration of the viral genome, by contrast, does not depend on the stage of replication and, by using probes for the whole genome, nuclei containing only part of the viral nucleic acid can be detected. The data reported here show on single sections that NISH is up to 30 times more sensitive than immunocytochemistry within a given lesion. Overall, the ratio of NISH and immunocytochemical positive to immunocytochemical positive cells was 6-3 for

SPECIFICITY OF STAINING WITH MONOCLONAL ANTI-HPV16 L1 AND POLYCLONAL ANTI-BPV

This is summarised in table 3. Although the antibody 5A4 was raised against the L1 protein of HPV16, it also binds to the capsid protein of HPV33, but not 6, 11, 18 or 31. No lesion was available to investigate HPV35. Antibodies 3D1 and 8C4 behaved similarly to 5A4. Antibody 1C6, however, also detected the capsid protein of HPV18 (fig 3). The ability of 1C6, 3D1, and 8C4 to detect the HPV31 capsid protein, however, could not be investigated due to the lack of biopsy specimens infected with HPV31.
ND 8C4 typing HPV with one or more of the antibodies (table 5).

Polyclonal xBPV

These negative Antibody HPV type serial sections were cut from each case. Five sections were used for HPV typing by NISH procedure used in this study, which has been shown to have a sensitivity of less than 40 viral copies.20

Diagnostic specificity does not, however, imply specificity. Immunocytochemistry with these antibodies does not detect lesions in which the viral nucleic acid is present, but the L1 gene is not being transcribed, or in which only part of the viral genome remains. Data presented in table 1 showed that in condylomata infected with a variety of viral subtypes many more cells contain viral nucleic acid than contain capsid protein. Moreover, reversal of the double staining procedure shows that all nuclei containing viral capsid protein also contain viral nucleic acid. Similarly, many lesions which contain viral genome, as shown by NISH, produce no signal with the four monoclonal antibodies. Notably, the absence of antibody staining does not correlate with the histological grade of the lesion or the presence of koilocytes. Direct demonstration of viral nucleic acid by situ hybridisation is therefore both more sensitive and more specific than the detection of viral capsid protein by immunocytochemistry.

The technique described here permits the demonstration of antigen and nucleic acid in the same cells in one tissue section. The greater sensitivity and specificity of NISH compared with capsid protein antibodies shows the greater diagnostic applicability of NISH over immunocytochemistry for HPV infection.

Addendum

The identification of two lesions infected with HPV35 as shown by high stringency in situ hybridisation has permitted further analysis of the specificity of the four antibodies used in this study. Capsid protein was detected in both cases by both the polyclonal antiserum to bovine papillomavirus and monoclonal antibody 1C6. 5A4, 3D1, and 8C4 gave no reaction. These observations show further the wider reactivity of antibody 1C6 compared with the other three.

This work was supported by grants from the Cancer Research Campaign UK (J O'D McGee).

We thank Drs P S Shepherd and D J McCance, Guys Hospital, London for kindly donating the monoclonal antibodies.


1C6, 7-0 for 8C4, 8-2 for 3D1 and 4-6 for 5A4. Similarly, lesions in which part or all of the viral genome is present can be detected independent of the production of the capsid protein. Thus both the relative and diagnostic sensitivities of NISH are superior to those of capsid protein immunocytochemistry for HPV detection at the dilutions of antibodies used here. It should be noted that the diagnostic sensitivity of NISH compared with immunocytochemistry depends on the protein detected by immunocytochemistry: the detection of the immediate early and early antigens of cytomegalovirus by immunocytochemistry is of equivalent diagnostic sensitivity to NISH, as assessed by analysis of parallel sections.21

The use of monoclonal antibodies to viral gene products has been advocated as a method of achieving diagnostic specificity.9 The L1 genes, however, which encode for the capsid proteins of HPV, share up to 88% of their nucleotide and 92% of their amino acid sequences.22 Thus it is not surprising that hybridomas produced at random may secrete antibodies which cross react with different HPV subtypes. From a diagnostic point of view, an antibody would be of use if it were capable of distinguishing either individual HPV subtypes or groups of viruses associated with diverse clinical behaviour. Thus antibodies 5A4, 3D1, and 8C4 are of limited use as they detect both HPV16 and 33 capsid proteins without cross reacting with HPV18 or, in the case of 5A4, HPV31. 1C6, however, also cross reacts with the L1 protein of HPV18 and can therefore differentiate the major subtypes associated with malignant progression from those associated with benign lesions. Although this antibody cross reaction could, in theory, be explained by the presence of multiple infections, all cases examined in this study were positive with only one viral probe at high stringency. If a second viral type were present in sufficient amounts to produce detectable capsid protein, it would be detectable using the NISH procedure used in this study, which has been shown to have a sensitivity of less than 40 viral copies.20

Diagnostic specificity does not, however, imply specificity. Immunocytochemistry with these antibodies does not detect lesions in which the viral nucleic acid is present, but the L1 gene is not being transcribed, or in which only part of the viral genome remains. Data presented in table 1 showed that in condylomata infected with a variety of viral subtypes many more cells contain viral nucleic acid than contain capsid protein. Moreover, reversal of the double staining procedure shows that all nuclei containing viral capsid protein also contain viral nucleic acid. Similarly, many lesions which contain viral genome, as shown by NISH, produce no signal with the four monoclonal antibodies. Notably, the absence of antibody staining does not correlate with the histological grade of the lesion or the presence of koilocytes. Direct demonstration of viral nucleic acid by situ hybridisation is therefore both more sensitive and more specific than the detection of viral capsid protein by immunocytochemistry.

The technique described here permits the demonstration of antigen and nucleic acid in the same cells in one tissue section. The greater sensitivity and specificity of NISH compared with capsid protein antibodies shows the greater diagnostic applicability of NISH over immunocytochemistry for HPV infection.

Addendum

The identification of two lesions infected with HPV35 as shown by high stringency in situ hybridisation has permitted further analysis of the specificity of the four antibodies used in this study. Capsid protein was detected in both cases by both the polyclonal antiserum to bovine papillomavirus and monoclonal antibody 1C6. 5A4, 3D1, and 8C4 gave no reaction. These observations show further the wider reactivity of antibody 1C6 compared with the other three.

This work was supported by grants from the Cancer Research Campaign UK (J O'D McGee).

We thank Drs P S Shepherd and D J McCance, Guys Hospital, London for kindly donating the monoclonal antibodies.


Eponyms in pathology...

von STERNBERG, Karl (1872-1935) was an Austrian pathologist, born and trained in Vienna, who qualified in 1896. After working as assistant to Paltauf in Vienna he was made professor of pathology there in 1908. He described the characteristic giant cells of Hodgkin's disease in 1898, later described by Dorothy Reed (a pathologist at Johns Hopkins University, Baltimore) in 1906. He also wrote a paper on "lymphosarcoma-cell" leukaemia, sometimes called Sternberg's leukaemia.

GIARD, Alfred (1846-1908) was a Parisian biologist who was a staunch follower of the doctrine of Lamarck. In 1882 he described the genus of flagellate protozoan now called Giardia.

PANETTI, Joseph (1857-1890) was an Austrian physiologist, born in Vienna, who held chairs of physiology in Breslau and Vienna. In 1888 he described the secretary cells in the crypts of the small intestinal mucosa which now bear his name.

BETZ, Vladimir Aleksandrovič (1834-1894) was a Russian anatomist who was professor of anatomy in Kiev from 1868 to 1889. He described the large pyramidal cells of the motor cortex (Betz cells) in 1874.

A K Graham, C S Herrington and O McGee J

doi: 10.1136/jcp.44.2.96

Updated information and services can be found at:
http://jcp.bmj.com/content/44/2/96

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/